

BIOCON GROUP

FACT SHEET

June - 2022

| BIOCON LIMITED (CONSOLIDATED) | | | |
|--|-----------------|-----------------|-------------------|
| PROFIT & LOSS STATEMENT | | | (Rs. Crores) |
| Particulars | Q1'FY 23 | Q1'FY 22 | Variance % |
| <u>INCOME</u> | | | |
| Generics | 580 | 486 | 19% |
| Biosimilars | 977 | 758 | 29% |
| Novel Biologics | - | 11 | -100% |
| Research services | 645 | 595 | 8% |
| Inter-segment | (61) | (89) | -31% |
| Revenue from operations # | 2,140 | 1,761 | 22% |
| Other income | 78 | 47 | 65% |
| TOTAL REVENUE | 2,217 | 1,808 | 23% |
| <u>EXPENDITURE</u> | | | |
| Material & Power costs | 795 | 686 | 16% |
| Staff costs | 463 | 395 | 17% |
| Research & Development expenses* | 198 | 120 | 65% |
| Other expenses | 285 | 171 | 66% |
| Manufacturing, staff & other expenses | 1,740 | 1,371 | 27% |
| EBITDA | 478 | 437 | 9% |
| Interest & Finance charges | 20 | 20 | 2% |
| Depreciation & Amortisation | 217 | 195 | 12% |
| Share of loss / (profit) in JV / Associate, net | 43 | 56 | -23% |
| PBT | 197 | 166 | 19% |
| Taxes | 30 | 57 | -49% |
| NET PROFIT BEFORE MINORITY INTEREST | 167 | 108 | 54% |
| Minority interest | 23 | 24 | -4% |
| NET PROFIT FOR THE PERIOD | 144 | 84 | 71% |
| EPS Rs. | 1.2 | 0.7 | |
| <i># Licensing Income</i> | 9 | 10 | |
| <i>* Gross Research & Development expenses</i> | 223 | 136 | |

| BIOCON LIMITED (CONSOLIDATED) | | | (Rs. Crores) |
|--|--------------|--------------|--------------|
| PROFIT & LOSS STATEMENT | | | |
| Particulars | Q1' FY 23 | Q4' FY 22 | Variance % |
| INCOME | | | |
| Generics | 580 | 717 | -19% |
| Biosimilars | 977 | 982 | -1% |
| Novel Biologics | - | 12 | -100% |
| Research services | 645 | 758 | -15% |
| Inter-segment | (61) | (61) | 0% |
| Revenue from operations # | 2,140 | 2,409 | -11% |
| Other income | 78 | 67 | 16% |
| TOTAL REVENUE | 2,217 | 2,476 | -10% |
| EXPENDITURE | | | |
| Material & Power costs | 795 | 911 | -13% |
| Staff costs | 463 | 428 | 8% |
| Research & Development expenses* | 198 | 191 | 4% |
| Other expenses | 285 | 288 | -1% |
| Manufacturing, staff & other expenses | 1,740 | 1,817 | -4% |
| EBITDA | 478 | 659 | -28% |
| Interest & Finance charges | 20 | 11 | 94% |
| Depreciation & Amortisation | 217 | 212 | 2% |
| Share of loss / (profit) in JV / Associate, net | 43 | 53 | 100% |
| PBT BEFORE EXCEPTIONAL ITEM | 197 | 384 | -49% |
| Exceptional item, Net | - | (41) | -100% |
| PBT | 197 | 343 | -43% |
| Taxes | 30 | 76 | -61% |
| Taxes on exceptional item | - | (17) | -100% |
| NET PROFIT BEFORE MINORITY INTEREST | 167 | 284 | -41% |
| Minority interest | 23 | 46 | -50% |
| NET PROFIT FOR THE PERIOD | 144 | 239 | -39% |
| EPS Rs. | 1.2 | 1.99 | |
| NET PROFIT BEFORE EXCEPTIONAL ITEM | | | |
| | 144 | 262 | -45% |
| Exceptional item, net of taxes | - | (24) | |
| NET PROFIT FOR THE PERIOD | 144 | 239 | -39% |
| # Licensing Income | 9 | 9 | |
| * Gross Research & Development expenses | 223 | 232 | |

BIOCON LIMITED (CONSOLIDATED)

BALANCE SHEET

(Rs Crores)

| Particulars | June 30, 2022 | March 31, 2022 |
|---|---------------|----------------|
| ASSETS | | |
| Non-current assets | | |
| (a) Property, plant and equipment | 5,807 | 5,677 |
| (b) Capital work-in-progress | 3,560 | 3,420 |
| (c) Right-of-use assets | 262 | 267 |
| (d) Goodwill | 26 | 26 |
| (e) Other intangible assets | 590 | 599 |
| (f) Intangible assets under development | 733 | 690 |
| (g) Investment in associates and a joint venture | 91 | 8 |
| (h) Financial assets | | |
| Investments | 407 | 362 |
| Derivative assets | 118 | 147 |
| Other financial assets | 68 | 45 |
| (i) Income tax asset, net | 346 | 314 |
| (j) Deferred tax asset, net | 356 | 293 |
| (k) Other non-current assets | 188 | 163 |
| Non-current assets | 12,550 | 12,012 |
| Current assets | | |
| (a) Inventories | 2,534 | 2,298 |
| (b) Financial assets | | |
| Investments | 1,400 | 1,218 |
| Trade receivables | 1,946 | 2,058 |
| Cash and cash equivalents | 647 | 663 |
| Other bank balances | 880 | 1,085 |
| Derivative assets | 83 | 122 |
| Loans and advances | - | 67 |
| Other financial assets | 521 | 451 |
| (c) Other current assets | 500 | 421 |
| (c) Assets held for sale | - | - |
| Current assets | 8,511 | 8,382 |
| TOTAL - ASSETS | 21,061 | 20,394 |
| EQUITY AND LIABILITIES | | |
| Equity | | |
| (a) Equity share capital | 600 | 600 |
| (b) Other equity | 7,915 | 7,832 |
| Equity attributable to owners of the Company | 8,515 | 8,433 |
| Non-controlling interests | 1,033 | 1,038 |
| Total Equity | 9,548 | 9,470 |
| Non-current liabilities | | |
| (a) Financial liabilities | | |
| Borrowings | 4,345 | 3,999 |
| Lease liabilities | 222 | 222 |
| Derivative liabilities | 62 | 14 |
| Other financial liabilities | 1,507 | 1,503 |
| (b) Provisions | 94 | 92 |
| (c) Deferred tax liability, net | 57 | 52 |
| (d) Other non-current liabilities | 1,289 | 1,215 |
| Non-current liabilities | 7,575 | 7,096 |
| Current liabilities | | |
| (a) Financial liabilities | | |
| Borrowings | 981 | 906 |
| Lease liabilities | 20 | 21 |
| Trade payables | 1,715 | 1,609 |
| Derivative liabilities | 40 | 12 |
| Other financial liabilities | 299 | 363 |
| (b) Provisions | 139 | 131 |
| (c) Income tax liability, net | 197 | 162 |
| (d) Other current liabilities | 546 | 625 |
| (e) Liabilities classified as held for sale | - | - |
| Current liabilities | 3,938 | 3,828 |
| TOTAL - EQUITY AND LIABILITIES | 21,061 | 20,394 |